^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Source:
Title:

977P - Phase II study of brigatinib in patients with tyrosine kinase inhibitor (TKI)-naïve ROS1-rearranged advanced non-small cell lung cancer (NSCLC): Barossa cohort 1

Published date:
09/05/2022
Excerpt:
Brigatinib demonstrated encouraging antitumor activity in patients with TKI-naïve ROS1-rearranged advanced NSCLC.
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer

Published date:
05/27/2020
Excerpt:
Brigatinib demonstrated modest activity in crizotinib-resistant ROS1-rearranged NSCLC. Its intracranial and systemic activity should be assessed in correlation with the underlying molecular mechanism of crizotinib resistance.
DOI:
10.1007/s12094-020-02376-w